Antibody targeting of long-circulating lipidic nanoparticles does not increase tumor localization but does increase internalization in animal models - PubMed (original) (raw)
Antibody targeting of long-circulating lipidic nanoparticles does not increase tumor localization but does increase internalization in animal models
Dmitri B Kirpotin et al. Cancer Res. 2006.
Abstract
We describe evidence for a novel mechanism of monoclonal antibody (MAb)-directed nanoparticle (immunoliposome) targeting to solid tumors in vivo. Long-circulating immunoliposomes targeted to HER2 (ErbB2, Neu) were prepared by the conjugation of anti-HER2 MAb fragments (Fab' or single chain Fv) to liposome-grafted polyethylene glycol chains. MAb fragment conjugation did not affect the biodistribution or long-circulating properties of i.v.-administered liposomes. However, antibody-directed targeting also did not increase the tumor localization of immunoliposomes, as both targeted and nontargeted liposomes achieved similarly high levels (7-8% injected dose/g tumor tissue) of tumor tissue accumulation in HER2-overexpressing breast cancer xenografts (BT-474). Studies using colloidal gold-labeled liposomes showed the accumulation of anti-HER2 immunoliposomes within cancer cells, whereas matched nontargeted liposomes were located predominantly in extracellular stroma or within macrophages. A similar pattern of stromal accumulation without cancer cell internalization was observed for anti-HER2 immunoliposomes in non-HER2-overexpressing breast cancer xenografts (MCF-7). Flow cytometry of disaggregated tumors posttreatment with either liposomes or immunoliposomes showed up to 6-fold greater intracellular uptake in cancer cells due to targeting. Thus, in contrast to nontargeted liposomes, anti-HER2 immunoliposomes achieved intracellular drug delivery via MAb-mediated endocytosis, and this, rather than increased uptake in tumor tissue, was correlated with superior antitumor activity. Immunoliposomes capable of selective internalization in cancer cells in vivo may provide new opportunities for drug delivery.
Similar articles
- Sterically stabilized anti-HER2 immunoliposomes: design and targeting to human breast cancer cells in vitro.
Kirpotin D, Park JW, Hong K, Zalipsky S, Li WL, Carter P, Benz CC, Papahadjopoulos D. Kirpotin D, et al. Biochemistry. 1997 Jan 7;36(1):66-75. doi: 10.1021/bi962148u. Biochemistry. 1997. PMID: 8993319 - Anti-HER2 immunoliposomes: enhanced efficacy attributable to targeted delivery.
Park JW, Hong K, Kirpotin DB, Colbern G, Shalaby R, Baselga J, Shao Y, Nielsen UB, Marks JD, Moore D, Papahadjopoulos D, Benz CC. Park JW, et al. Clin Cancer Res. 2002 Apr;8(4):1172-81. Clin Cancer Res. 2002. PMID: 11948130 - Tumor targeting using anti-her2 immunoliposomes.
Park JW, Kirpotin DB, Hong K, Shalaby R, Shao Y, Nielsen UB, Marks JD, Papahadjopoulos D, Benz CC. Park JW, et al. J Control Release. 2001 Jul 6;74(1-3):95-113. doi: 10.1016/s0168-3659(01)00315-7. J Control Release. 2001. PMID: 11489487 - [PEG-liposome in DDS and clinical studies].
Maruyama K. Maruyama K. Nihon Rinsho. 1998 Mar;56(3):632-7. Nihon Rinsho. 1998. PMID: 9549348 Review. Japanese. - Future directions of liposome- and immunoliposome-based cancer therapeutics.
Park JW, Benz CC, Martin FJ. Park JW, et al. Semin Oncol. 2004 Dec;31(6 Suppl 13):196-205. doi: 10.1053/j.seminoncol.2004.08.009. Semin Oncol. 2004. PMID: 15717745 Review.
Cited by
- Lipid-Based Drug Delivery Systems in Cancer Therapy: What Is Available and What Is Yet to Come.
Yingchoncharoen P, Kalinowski DS, Richardson DR. Yingchoncharoen P, et al. Pharmacol Rev. 2016 Jul;68(3):701-87. doi: 10.1124/pr.115.012070. Pharmacol Rev. 2016. PMID: 27363439 Free PMC article. Review. - Targeting cancer cells in the tumor microenvironment: opportunities and challenges in combinatorial nanomedicine.
Linton SS, Sherwood SG, Drews KC, Kester M. Linton SS, et al. Wiley Interdiscip Rev Nanomed Nanobiotechnol. 2016 Mar-Apr;8(2):208-22. doi: 10.1002/wnan.1358. Epub 2015 Jul 7. Wiley Interdiscip Rev Nanomed Nanobiotechnol. 2016. PMID: 26153136 Free PMC article. Review. - Folate-conjugated gold nanoparticle as a new nanoplatform for targeted cancer therapy.
Samadian H, Hosseini-Nami S, Kamrava SK, Ghaznavi H, Shakeri-Zadeh A. Samadian H, et al. J Cancer Res Clin Oncol. 2016 Nov;142(11):2217-29. doi: 10.1007/s00432-016-2179-3. Epub 2016 May 21. J Cancer Res Clin Oncol. 2016. PMID: 27209529 Review. - Impact of tumor-specific targeting on the biodistribution and efficacy of siRNA nanoparticles measured by multimodality in vivo imaging.
Bartlett DW, Su H, Hildebrandt IJ, Weber WA, Davis ME. Bartlett DW, et al. Proc Natl Acad Sci U S A. 2007 Sep 25;104(39):15549-54. doi: 10.1073/pnas.0707461104. Epub 2007 Sep 17. Proc Natl Acad Sci U S A. 2007. PMID: 17875985 Free PMC article. - Therapeutic cell engineering with surface-conjugated synthetic nanoparticles.
Stephan MT, Moon JJ, Um SH, Bershteyn A, Irvine DJ. Stephan MT, et al. Nat Med. 2010 Sep;16(9):1035-41. doi: 10.1038/nm.2198. Epub 2010 Aug 15. Nat Med. 2010. PMID: 20711198 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Research Materials
Miscellaneous